|

nab-paclitaxel + gemcitabine Clinical Trials

6 actively recruiting trials across 1 location

Pipeline

Phase 2: 2Phase 3: 2Phase 1/2: 2

Top Sponsors

  • Jiangsu HengRui Medicine Co., Ltd.2
  • Fudan University1
  • Dartmouth-Hitchcock Medical Center1
  • Chinese PLA General Hospital1
  • Akeso1

Indications

  • Cancer6
  • First-line Treatment of Metastatic Pancreatic Cancer1
  • First-line Treatment of Advanced Pancreatic Cancer1
  • Pancreas Adenocarcinoma1
  • Pancreatic Cancer Metastatic1

Other5 trials

A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Phase 2
AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer
Phase 1/2
HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer
Phase 3
Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
Phase 3
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
Phase 1/2

Lebanon, New Hampshire1 trial

24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC

Dartmouth-Hitchcock Medical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.